Professor and Chairman
Cleveland Clinic
Brian Rubin, MD, PhD is Professor and Chair of Pathology of the Robert J. Tomsich Pathology and Laboratory Medicine Institute at the Cleveland Clinic. He received his PhD in molecular biology and his MD from Cornell University Medical College. He did his residency in Anatomic Pathology at Brigham and Women’s Hospital and received fellowship training in soft tissue pathology, bone pathology, and cancer genetics.
Dr. Rubin has dedicated his career to a better understanding of the diagnosis and classification of soft tissue neoplasms, especially sarcomas, where he is a prominent figure nationally and internationally. He is widely regarded as a thought leader in the field and is a founding member of the International Society of Bone and Soft Tissue Pathology. His laboratory is focused on understanding the pathogenesis of sarcomas with the major aim of developing targeted therapies. Dr. Rubin has published over 200 peer reviewed journal articles and is the author of numerous reviews and book chapters. He was a member of the working group that authored the WHO Classification of Tumours of Bone and Soft Tissue in 2002 and 2012. He is well known for his work on gastrointestinal stromal tumor (GIST) and other cancers such as melanoma that are driven by oncogenically-activated KIT receptor tyrosine kinase. His group also characterized a novel gene fusion in epithelioid hemangioendothelioma (EHE), a sarcoma with endothelial differentiation. This latest development has allowed them to initiate studies of EHE biology with the goal of developing targeted therapies to treat EHE. Finally, Dr. Rubin has led his team in the Robert J. Tomsich Pathology and Laboratory Medicine Institute to launch, expand, and maintain SARS-CoV-2 (COVID) testing during the recent unprecedented pandemic.
